![Reimar Schlingensiepen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Reimar Schlingensiepen
Vorstandsvorsitzender bei AudioCure Pharma GmbH
Profil
Reimar Schlingensiepen is the founder of Isarna Therapeutics GmbH, which was founded in 1998.
He held the title of Chief Operating Officer from 2009 to 2012.
Currently, he is the Chief Executive Officer at AudioCure Pharma GmbH, a position he has held since 2017.
Dr. Schlingensiepen's former job was as the Chief Executive Officer at JADO Technologies GmbH from 2010 to 2014.
Aktive Positionen von Reimar Schlingensiepen
Unternehmen | Position | Beginn |
---|---|---|
AudioCure Pharma GmbH
![]() AudioCure Pharma GmbH Pharmaceuticals: MajorHealth Technology AudioCure Pharma GmbH provides preclinical research and clinical development of novel pharmacotherapies to treat disorders of the inner ear. It engages in the clinical development of drug candidates in neurodegenerative disease indications. The firm's offer medicine for the treatment of acute and chronic hearing impairments via local, regenerative therapy of the damaged nerve cells in the inner ear. The company was founded by Hans Rommelspacher in 2010 and is headquartered in Berlin, Germany. | Vorstandsvorsitzender | 22.05.2017 |
Ehemalige bekannte Positionen von Reimar Schlingensiepen
Unternehmen | Position | Ende |
---|---|---|
JADO Technologies GmbH
![]() JADO Technologies GmbH Drugstore ChainsRetail Trade JADO Technologies GmbH develops novel small molecule drugs. It offers drugs based on an unrivalled insight into cell membrane biology and the role of specific cellular domains, including lipid rafts. The firm's technology provides an insight into diverse pathological mechanisms and drives the design of innovative drugs with new modes of action. The company was founded by Teymuras Kurzchalia, Hans-Joachim Knölker, Gary Jennings, Kai Simons and Marino Zerial in 2001 and is headquartered in Dresden, Germany. | Vorstandsvorsitzender | 17.04.2014 |
Isarna Therapeutics GmbH
![]() Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Isarna Therapeutics GmbH
![]() Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Health Technology |
JADO Technologies GmbH
![]() JADO Technologies GmbH Drugstore ChainsRetail Trade JADO Technologies GmbH develops novel small molecule drugs. It offers drugs based on an unrivalled insight into cell membrane biology and the role of specific cellular domains, including lipid rafts. The firm's technology provides an insight into diverse pathological mechanisms and drives the design of innovative drugs with new modes of action. The company was founded by Teymuras Kurzchalia, Hans-Joachim Knölker, Gary Jennings, Kai Simons and Marino Zerial in 2001 and is headquartered in Dresden, Germany. | Retail Trade |
AudioCure Pharma GmbH
![]() AudioCure Pharma GmbH Pharmaceuticals: MajorHealth Technology AudioCure Pharma GmbH provides preclinical research and clinical development of novel pharmacotherapies to treat disorders of the inner ear. It engages in the clinical development of drug candidates in neurodegenerative disease indications. The firm's offer medicine for the treatment of acute and chronic hearing impairments via local, regenerative therapy of the damaged nerve cells in the inner ear. The company was founded by Hans Rommelspacher in 2010 and is headquartered in Berlin, Germany. | Health Technology |